Value of 18F-fluorocholine PET/CT in predicting response to radical radiotherapy in patients with localized prostate cancer

D'Amico, 1998, Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer, JAMA, 280, 969, 10.1001/jama.280.11.969 Piert, 2009, Detection of aggressive primary prostate cancer with 11C-choline PET/CT using multimodality fusion techniques, J Nucl Med, 1585, 10.2967/jnumed.109.063396 Chang, 2011, Histopathological correlation of 11C-choline PET scans for target volume definition in radical prostate radiotherapy, Radiother Oncol, 99, 187, 10.1016/j.radonc.2011.03.012 Evangelista, 2013, «Comparative studies of radiolabeled choline positron emission tomography, histology of primary tumor and other imaging modalities in prostate cancer: a systematic review and meta-analysis, Clin Transl Imaging, 1, 99, 10.1007/s40336-013-0016-0 Colombiè, 2015, Prognostic value of metabolic parameters and clinical impact of 18F-fluorocholine PET/CT in biochemical recurrent prostate cancer, Eur J Nucl Med Mol Imaging, 1784, 10.1007/s00259-015-3123-5 Viani, 2009, Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials, Int J Radiat Oncol, Biol Phys, 1405, 10.1016/j.ijrobp.2008.10.091 Pinkawa, 2009, Dose-escalation using intensity-modulated radiotherapy for prostate cancer - Evaluation of the dose distribution with and without 18F-choline PET-CT detected simultaneous integrated boost, Radiother Oncol, 213, 10.1016/j.radonc.2009.07.014 NCCN, 2017 Miralbell, 2012, Dose-Fractionation Sensitivity of Prostate Cancer Deduced From Radiotherapy Outcomes of 5,969 Patients in Seven International Institutional Datasets: α/β = 1.4 (0.9–2.2) Gy, Int J Radiat, Biol Phys, 82, e17, 10.1016/j.ijrobp.2010.10.075 R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL <https://www.R-project.org/>; 2020. Giovacchini, 2014, 11C-choline PET/CT predicts prostate cancer-specific survival in patients with biochemical failure during androgen deprivation therapy, J Nucl Med, 55, 233, 10.2967/jnumed.113.123380 Giovacchini, 2015, [11C]choline PET/CT predicts survival in hormone-naive prostate cancer patients with biochemical failure after radical prostatectomy, Eur J Nucl Med Mol Imaging, 42, 877, 10.1007/s00259-015-3015-8 Kwee, 2014, Prognosis related to metastatic burden measured by 18F-fluorocholine PET/CT in castration-resistant prostate cancer, J Nucl Med, 55, 905, 10.2967/jnumed.113.135194 Reske, 2006, Imaging prostate cancer with 11C-choline PET/CT, J Nucl Med, 1249 Jiménez Londoňo, 2017, Role of 18F-Choline PET/CT in guiding biopsy in patients with raised PSA levels and previous negative biopsy for prostate cancer, 241 Igerc, 2008, «The value of 18F-Choline PET/CT in patients with elevated PSA-level and negative prostate needle biopsy for localisation of prostate cancer, Eur J Nucl Mol Imaging, 35, 976, 10.1007/s00259-007-0686-9 Crawford, 2001, Prostate cancer pathology, screening, and epidemiology, Rev Urol, 2 Giovacchini, 2008, (11)C-choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy, Eur J Nucl Med Mol Imaging, 1065, 10.1007/s00259-008-0716-2 Sutinen, 2004, Kinetics of (11)C-choline uptake in prostate cancer: a PET study, Eur J Nucl Med Mol Imaging, 317, 10.1007/s00259-003-1377-9 Evangelista, 2016, The effects of androgen deprivation therapy on the 18F-choline uptake in prostate cancer patients undergoing neoadjuvant treatment, Q J Nucl Med Mol Imaging Chan, 2017, Effect of androgen deprivation therapy on intraprostatic tumour volume identified on 18F choline PET/CT for prostate dose painting radiotherapy, Br J Radiol, 90, 16, 10.1259/bjr.20160818 Challapalli, 2014, Exploring the potential of [11C]choline-PET/CT as a novel imaging biomarker for predicting early treatment response in prostate cancer, Nucl Med Commun, 20, 10.1097/MNM.0000000000000014 Pucar, 2007, Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence, Int J Radiat Oncol, Biol Phys, 69, 62, 10.1016/j.ijrobp.2007.03.065 Cellini, 2002, Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning, Int J Radiat Oncol, Biol Phys, 53, 595, 10.1016/S0360-3016(02)02795-5 Zelefsky, 1998, Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer, Int J Radiat Oncol, Biol Phys, 41, 491, 10.1016/S0360-3016(98)00091-1 Pollack, 2000, External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era, Int J Radiat Oncol, Biol Phys, 48, 507, 10.1016/S0360-3016(00)00620-9 Ippolito, 2012, Intensity-modulated radiotherapy with simultaneous integrated boost to dominant intraprostatic lesion: preliminary report on toxicity, Am J Clin Oncol, 35, 158, 10.1097/COC.0b013e318209cd8f Sundahl, 2016, Combining high dose external beam radiotherapy with a simultaneous integrated boost to the dominant intraprostatic lesion: analysis of genito-urinary and rectal toxicity, Radiother Oncol, 119, 398, 10.1016/j.radonc.2016.04.031 Monninkhof, 2018, Standard whole prostate gland radiotherapy with and without lesion boost in prostate cancer: Toxicity in the FLAME randomized controlled trial, Radiother Oncol, 127, 74, 10.1016/j.radonc.2017.12.022 Kerkmeijer, 2021, Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial, J Clin Oncol, 10.1200/JCO.20.02873 Park, 2010, Validation of automatic target volume definition as demonstrated for 11C-Choline PET/CT of human prostate cancer using multi-modality fusion techniques, Acad Radiol, 17, 614, 10.1016/j.acra.2010.01.003 Chang, 2012, Intensity modulated radiation therapy dose painting for localized prostate cancer using 11C-choline positron emission tomography scans, Int J Radiat Oncol, Biol Phys, 83, e691, 10.1016/j.ijrobp.2012.01.087 Wibmer, 2016, Molecular imaging of prostate cancer, Radiographics, 36, 142, 10.1148/rg.2016150059 Hofman, 2020, proPSMA Study Group Collaborators. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study, Lancet, 395, 1208, 10.1016/S0140-6736(20)30314-7 Fendler, 2019, Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer, Clin Cancer Res, 25, 7448, 10.1158/1078-0432.CCR-19-1050 Thomas, 2018, 68Ga-PSMA-PET/CT imaging of localized primary prostate cancer patients for intensity modulated radiation therapy treatment planning with integrated boost, Eur J Nucl Med Mol Imaging, 45, 1170, 10.1007/s00259-018-3954-y Goodman, 2019, Dosimetric evaluation of PSMA PET-delineated dominant intraprostatic lesion simultaneous infield boosts, Adv Radiat Oncol, 5, 212, 10.1016/j.adro.2019.09.004